STOCK TITAN

Globus Medical director Tobin sells 37,662-share block

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Globus Medical Inc. (GMED) director James R. Tobin exercised options for 15,000 Class A shares at an exercise price of $65.05 per share, 21,458 at $53.27, and 5,208 at $43.58 on November 10, 2026. He sold 37,662 shares at a weighted average price of $75.1025 per share, with reported sale prices ranging from $74.58 to $75.53, and another 4,004 shares at a weighted average price of $75.6836, with reported sale prices from $75.60 to $76.05. No Rule 10b5-1 plan is reported.

Insider TOBIN JAMES R
Role Director
Sold 41,666 shs ($3.13M)
Approx. gross sale proceeds $3.13M
Approx. exercise cost $2.35M
Approx. pre-tax spread $786K
Share of Position Sold 100%
Type Security Shares Price Value
Exercise Stock Option (Right to Buy Class A Common Stock) F3 15,000 $0.00 $0.00
Exercise Stock Option (Right to Buy Class A Common Stock) F4 21,458 $0.00 $0.00
Exercise Stock Option (Right to Buy Class A Common Stock) F5 5,208 $0.00 $0.00
Exercise Class A Common Stock 15,000 $65.05 $976K
Exercise Class A Common Stock 21,458 $53.27 $1.14M
Exercise Class A Common Stock 5,208 $43.58 $227K
Sale Class A Common Stock F1 37,662 $75.1025 $2.83M
Sale Class A Common Stock F2 4,004 $75.6836 $303K
Holdings After Transaction: Stock Option (Right to Buy Class A Common Stock) — 0 options (Direct); Class A Common Stock — 0 shares (Direct)
Holdings Before and After: Stock Option (Right to Buy Class A Common Stock), 41,666 to 0 options (Direct); Class A Common Stock, 0 to 0 shares (Direct)
Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (5)
  1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.58 to $75.53, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.60 to $76.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
  3. F3. These options were granted on January 14, 2021 and are fully vested.
  4. F4. These options were granted on January 22, 2020 and are fully vested.
  5. F5. These options were granted on January 22, 2019 and are fully vested.
Options exercised and exercise price 15,000 shares at $65.05 per share November 10, 2026
Options exercised and exercise price 21,458 shares at $53.27 per share November 10, 2026
Options exercised and exercise price 5,208 shares at $43.58 per share November 10, 2026
Class A shares sold 37,662 shares at a weighted average $75.1025 per share November 10, 2026; reported sale prices ranged from $74.58 to $75.53
Class A shares sold 4,004 shares at a weighted average $75.6836 per share November 10, 2026; reported sale prices ranged from $75.60 to $76.05
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
fully vested financial
"These options were granted on January 14, 2021 and are fully vested."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GMED shares did James R. Tobin sell on November 10, 2026?

James R. Tobin sold 37,662 Class A shares at a weighted average $75.1025 per share and 4,004 shares at a weighted average $75.6836 per share. The reported sale-price ranges were $74.58 to $75.53 and $75.60 to $76.05, respectively. No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
TOBIN JAMES R

(Last)(First)(Middle)
VALLEY FORGE BUSINESS CENTER
2560 GENERAL ARMISTEAD AVENUE

(Street)
AUDUBON PENNSYLVANIA 19403

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock11/10/2026M15,000A$65.0515,000D
Class A Common Stock11/10/2026M21,458A$53.2736,458D
Class A Common Stock11/10/2026M5,208A$43.5841,666D
Class A Common Stock11/10/2026S37,662D$75.1025(1)4,004D
Class A Common Stock11/10/2026S4,004D$75.6836(2)0D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)$65.0511/10/2026M15,000 (3)01/14/2031Class A Common Stock15,000$00D
Stock Option (Right to Buy Class A Common Stock)$53.2711/10/2026M21,458 (4)01/22/2030Class A Common Stock21,458$00D
Stock Option (Right to Buy Class A Common Stock)$43.5811/10/2026M5,208 (5)01/22/2029Class A Common Stock5,208$00D
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.58 to $75.53, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.60 to $76.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
3. These options were granted on January 14, 2021 and are fully vested.
4. These options were granted on January 22, 2020 and are fully vested.
5. These options were granted on January 22, 2019 and are fully vested.
/s/ Kelly G. Huller, Attorney-in-Fact11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading